Chemomab Therapeutics (CMMB) and Scipher Medicine to merge in $150m reverse deal

Chemomab Therapeutics Ltd. (NASDAQ: CMMB) and privately held Scipher Medicine Corporation have entered into a definitive all-stock merger agreement that will combine the two companies under the Scipher Medicine Corporation banner and simultaneously deliver the private precision immunology developer a public listing on the Nasdaq exchange through the Chemomab Therapeutics shell. The combined company is valued at approximately 150 million dollars on a pre-money basis before a concurrent 30 million dollar private placement, giving the newly merged entity cash runway into the second half of 2028 and enough capacity to advance nebokitug, Chemomab Therapeutics’ first-in-class anti-CCL24 antibody, into a Phase 2 trial for the treatment of rheumatoid arthritis with an AI-guided patient enrollment design built around Scipher Medicine Corporation’s proprietary PrismRA molecular signature test.

Chemomab Therapeutics shares fell 13.72 percent in pre-market trading to 2.39 dollars on the Nasdaq exchange following the announcement, a typical reaction pattern for micro-cap acquisition targets where existing shareholders absorb dilution risk and inherit a materially different underlying business, but the reverse merger structure also delivers Chemomab Therapeutics shareholders contingent value rights tied to specified nebokitug milestones and a 32 percent stake in a business with genuine commercial revenue traction. The transaction is expected to close in the fourth quarter of 2026, with top-line Phase 2 rheumatoid arthritis data anticipated in the first half of 2028, and it represents one of the more distinctive reverse merger structures in the current biotech financing environment because it combines an established precision medicine commercial business with a de-risked clinical asset that has already generated positive Phase 2 fibrosis data and independent AI-derived target validation.

What does the Scipher Medicine and Chemomab Therapeutics merger actually change in precision immunology

The transaction is structurally different from a conventional biotech acquisition or a standard reverse merger. Scipher Medicine Corporation is not a shell-seeking clinical-stage developer looking for a listing vehicle. It is a revenue-generating precision immunology company that already operates three distinct commercial businesses, and it is using the reverse merger to accelerate access to the public capital markets rather than as its primary business model transformation. The three commercial pillars include biopharma partnerships using Scipher Medicine Corporation’s proprietary preclinical and clinical de-risking platform, an immunology data business anchored on one of the industry’s largest non-oncology clinico-genomic data assets covering more than 3 million rheumatology patients, and the commercial PrismRA molecular signature test, which is the only precision medicine test for rheumatoid arthritis reimbursed by the Centers for Medicare and Medicaid Services.

The Chemomab Therapeutics contribution is nebokitug, an anti-CCL24 antibody with a differentiated dual mechanism addressing both inflammatory and fibrotic drivers of disease. Nebokitug has demonstrated a favorable safety and tolerability profile in a completed Phase 2 trial in fibrotic indications, has produced measurable reductions in inflammatory and fibrotic biomarkers including TGF-beta in a dose-dependent manner in the Phase 2 SPRING trial, and has been independently identified as the highest-ranked clinical-stage rheumatoid arthritis target for efficacy by Scipher Medicine Corporation’s AI Network Medicine platform. That independent AI validation is the intellectual justification for redirecting nebokitug from its original fibrosis-focused development plan toward rheumatoid arthritis, and it is central to the analytical case for the transaction.

The strategic implication is that the combined company will be one of the very few precision immunology businesses that owns both a differentiated clinical asset in rheumatoid arthritis and the platform capability to conduct AI-guided patient selection at the trial design stage. That combination has been the theoretical target of precision medicine advocates for more than a decade, and it has struggled to materialise in practice because the diagnostic developers and the therapeutic developers have historically operated in separate value chains with divergent economic incentives. By bringing PrismRA and nebokitug under one corporate roof, the transaction removes that misalignment and creates a testable case for whether an AI-guided precision medicine approach can materially improve the probability of success for a Phase 2 rheumatoid arthritis programme.

How does nebokitug’s CCL24 mechanism differentiate it in a rheumatoid arthritis market dominated by TNF inhibitors

Rheumatoid arthritis affects approximately 1.6 million adults in the United States and more than 20 million patients globally, and the treatment paradigm has been dominated for two decades by tumor necrosis factor alpha inhibitors led by AbbVie Inc. Humira, Amgen Inc. Enbrel, and various biosimilars. Adjacent mechanisms have expanded the treatment armamentarium through JAK inhibitors including AbbVie Inc. Rinvoq, Pfizer Inc. Xeljanz, and Eli Lilly and Company Olumiant, the interleukin-6 pathway through Roche Holding AG Actemra, and the CTLA-4 axis through Bristol-Myers Squibb Company Orencia. Despite this therapeutic breadth, approximately one in three rheumatoid arthritis patients still fail to achieve adequate response on TNF inhibitor therapy, which is the entire commercial rationale behind Scipher Medicine Corporation’s PrismRA test and creates the addressable population for a mechanistically differentiated candidate like nebokitug.

CCL24, also known as eotaxin-2, is a chemokine that plays a pro-inflammatory and pro-fibrotic role in multiple autoimmune conditions, and its involvement in rheumatoid arthritis pathology was first described in peer-reviewed literature more than 15 years ago. Subsequent independent research has established that CCL24 is upregulated in rheumatoid arthritis patients regardless of disease onset and that higher CCL24 expression correlates with greater disease severity and a subsequent need for advanced therapies. Nebokitug directly blocks CCL24, and its dual anti-inflammatory and anti-fibrotic activity distinguishes it from mechanisms that address only inflammatory signaling and leave the fibrotic component of rheumatoid arthritis pathology untreated.

The mechanistic differentiation matters commercially because it targets a population that is meaningfully underserved by the existing treatment landscape. Patients who fail TNF inhibitor therapy and cycle through second-line agents represent a subset of the total addressable market that carries substantially higher per-patient economic value because they have already demonstrated payer willingness to fund high-cost therapy and because their alternative treatment options are limited. If nebokitug can demonstrate efficacy in a PrismRA-enriched population of predicted TNF inhibitor non-responders, the commercial positioning shifts from competing directly with first-line TNF inhibitors to establishing an evidence base for a differentiated second-line indication, which is a more defensible entry strategy for a small-cap precision immunology developer.

Why is Scipher Medicine choosing a reverse merger over an IPO to access the public markets in Q4 2026

The choice of a reverse merger structure over a conventional initial public offering is not simply a financing preference. It reflects the current state of biotech public equity markets, the specific attributes of the Chemomab Therapeutics vehicle, and the strategic value of combining nebokitug with the Scipher Medicine Corporation platform. The biotech IPO window remains structurally challenged for early-stage precision medicine and diagnostic companies, and companies pursuing conventional listings have often faced valuation resets, extended marketing timelines, and lower proceeds than pre-marketing indications would suggest. A reverse merger with a Nasdaq-listed clinical-stage biotech avoids that structural friction while delivering an immediate public listing.

The Chemomab Therapeutics vehicle is particularly well suited to the transaction because it brings a clinical asset that Scipher Medicine Corporation has independently validated as high-value through its AI Network Medicine platform. That is materially different from a typical reverse merger scenario in which the target vehicle is essentially a listing shell with negligible ongoing value to the acquirer. Nebokitug’s prior Phase 2 SPRING trial data in fibrotic conditions provide substantive safety and biomarker evidence, and the CCL24 mechanistic literature provides scientific rationale independent of Chemomab Therapeutics’ own development thesis. The combined effect is that the Chemomab Therapeutics contribution is more than a listing pathway. It is a de-risked clinical programme.

The financing architecture also supports the reverse merger choice. The concurrent 30 million dollar private placement, led by Northpond Ventures and joined by Khosla Ventures, Blue Owl Healthcare Opportunities, and funds managed by Neuberger Berman, delivers immediate capital alongside the merger close and provides the combined company with cash runway into the second half of 2028. That runway timeline is aligned precisely with the anticipated first-half 2028 topline Phase 2 rheumatoid arthritis data readout, meaning the combined company can reach its most important clinical value inflection point without requiring a subsequent capital raise under duress.

What role does the $30 million private placement led by Northpond Ventures play in the combined company’s runway

The concurrent private placement financing is one of the most analytically important components of the transaction. Northpond Ventures leads the syndicate, which includes Khosla Ventures, Blue Owl Healthcare Opportunities, funds managed by Neuberger Berman, and other major investors. This is a high-quality institutional syndicate for a business at this stage, and each of the named participants brings different strategic value beyond the immediate capital. Northpond Ventures is a specialist life sciences investor known for building large positions in precision medicine and platform biology companies. Khosla Ventures brings deep AI and technology investment credibility. Blue Owl Healthcare Opportunities and Neuberger Berman bring public equity market presence and follow-on financing capacity.

The 30 million dollar quantum is calibrated to the specific milestones the combined company needs to reach without requiring additional dilutive capital. Combined with the pre-transaction cash position of Chemomab Therapeutics and the existing Scipher Medicine Corporation revenue base from its three commercial businesses, the funding provides operational runway into the second half of 2028 and covers the full duration of the planned Phase 2 rheumatoid arthritis trial with nebokitug. That runway coverage is the essential precondition for the market to value the transaction on the merits of the clinical thesis rather than on the risk of imminent dilution.

The composition of the syndicate also carries significant signalling value. Institutional investors of this quality performing extensive diligence on a private company transitioning to public markets is a strong endorsement of the underlying platform economics, the nebokitug clinical thesis, and the leadership team assembled to execute the strategy. If the combined company subsequently faces public market volatility during 2027, the presence of these specialist investors on the register creates natural liquidity providers and reduces the risk of forced selling that often afflicts small-cap biotechs after reverse mergers. That structural stability is a distinct advantage over conventional IPO alternatives where post-listing share price performance is often driven by non-fundamental technical selling.

How does the AI-powered Phase 2 trial design using PrismRA reshape rheumatoid arthritis clinical trial economics

The Phase 2 rheumatoid arthritis trial for nebokitug will use standard 12-week FDA-recognised rheumatoid arthritis endpoints, but the enrollment design incorporates AI-guided patient selection using Scipher Medicine Corporation’s validated PrismRA multi-modal, multi-omic test. This is a genuinely differentiated trial design that could materially improve the probability of demonstrating a clinically meaningful treatment effect. Standard rheumatoid arthritis trials enroll heterogeneous populations that include TNF inhibitor responders and non-responders, treatment-naive and treatment-experienced patients, and patients with varying disease activity scores. That heterogeneity dilutes measurable treatment effects and drives the high failure rates that characterise clinical trials in this therapeutic area.

By using PrismRA to guide enrollment toward a molecular signature-defined patient population, the trial can concentrate treatment exposure on patients whose underlying disease biology aligns with nebokitug’s CCL24 mechanism of action. That precision approach mirrors the successful oncology precision medicine playbook that has transformed drug development in genomically defined cancers, and it applies that playbook for the first time at scale to rheumatoid arthritis, where precision medicine adoption has lagged materially behind oncology. If the trial demonstrates the anticipated efficacy signal, it will simultaneously validate the nebokitug therapeutic thesis and the AI-guided trial design methodology, creating value on two independent axes.

The economic implications for the combined company are substantial. AI-guided precision trials that reach primary endpoint success support both a stronger licensing negotiation position with potential development or commercialization partners and a higher probability of subsequent Phase 3 success. They also strengthen the Scipher Medicine Corporation platform business by generating additional real-world evidence for PrismRA and validating the SPECTRA Rx AI Network Medicine platform in a prospective clinical setting. The read-across for future business development conversations with biopharma partners is meaningful, because a successful nebokitug Phase 2 result would demonstrate the Scipher Medicine Corporation platform delivering value at every stage of drug development from target identification through pivotal trial design.

Why is the 68/32 ownership split and the CVR structure the analytically important detail of this transaction

The ownership economics establish that Scipher Medicine Corporation shareholders will control approximately 68 percent of the combined company on a fully diluted basis immediately prior to the private placement, while Chemomab Therapeutics shareholders will hold approximately 32 percent. That split reflects the relative valuations the negotiating parties assigned to Scipher Medicine Corporation’s revenue-generating platform business and PrismRA franchise, and to Chemomab Therapeutics’ nebokitug clinical asset and public listing. The 68 percent Scipher Medicine Corporation share confirms that the underlying transaction is primarily an ascent to public markets for the precision immunology business, with Chemomab Therapeutics providing a valuable but secondary contribution.

The contingent value rights structure attached to Chemomab Therapeutics shareholders is the mechanism that aligns the value split with subsequent nebokitug clinical progress. Chemomab Therapeutics shareholders will receive CVRs providing the opportunity to receive additional value upon the achievement of certain specified milestones related to nebokitug, subject to the terms and conditions of the CVR agreement. That structure protects legacy Chemomab Therapeutics shareholders against the risk that the combined company achieves substantial nebokitug success after their equity contribution has been diluted to 32 percent, and it aligns their economic interest with continued clinical execution.

The negotiated ownership split also has practical implications for combined company governance. A 68 percent equity holder base rarely leaves meaningful minority protection questions unresolved, but the presence of a Chemomab Therapeutics director representation on the combined board, the inclusion of specified nebokitug-related milestones in the CVR structure, and the preservation of the Chemomab Therapeutics team focused on nebokitug development all provide mechanisms to ensure that the legacy clinical asset receives appropriate strategic attention. Reverse mergers historically underperform on integration when the acquirer treats the target purely as a listing vehicle, and the deal architecture appears explicitly designed to avoid that outcome.

What are the execution, clinical, and regulatory risks that could complicate closing and the H1 2028 Phase 2 readout

The primary closing risk is standard reverse merger regulatory and shareholder approval friction. The transaction requires customary regulatory approvals, filing of proxy materials with the Securities and Exchange Commission, majority shareholder approval by both Chemomab Therapeutics and Scipher Medicine Corporation shareholders, and successful completion of the concurrent 30 million dollar private placement. Any adverse development between announcement and the anticipated fourth-quarter 2026 close, including material adverse changes in the business condition of either party or dislocation in the small-cap biotech financing markets, could complicate closing on the current terms and force a re-cut of the transaction.

The most significant clinical risk sits with the Phase 2 rheumatoid arthritis trial design and execution. AI-guided precision medicine trials are analytically compelling but operationally complex, and successful execution requires accurate PrismRA test administration at enrolling sites, timely molecular signature analysis, and appropriate patient screening protocols. Any friction in that operational chain would either delay the H1 2028 topline readout or dilute the enrollment precision that the trial design is designed to deliver. The combined company will need to invest in trial operations infrastructure and site management capabilities to protect the integrity of the AI-guided design.

The regulatory and reimbursement landscape adds a third risk vector. The FDA has been increasingly supportive of precision medicine trial designs, but the specific interpretation of AI-guided patient selection under the Accelerated Approval or Full Approval pathways will need to be negotiated during the trial design finalisation. Payer response to a subsequent commercial product priced for a molecular signature-defined population is also uncertain, and reimbursement decisions from the Centers for Medicare and Medicaid Services and commercial payers will shape the ultimate commercial value of a nebokitug approval. The precedent set by PrismRA reimbursement is favourable but does not automatically translate to a linked therapeutic product.

Key takeaways on what this reverse merger means for CMMB shareholders, private biotech IPO alternatives, and precision RA

• Chemomab Therapeutics Ltd. and Scipher Medicine Corporation have entered into an all-stock merger agreement valued at approximately 150 million dollars on a pre-money basis, with a concurrent 30 million dollar private placement from an institutional syndicate led by Northpond Ventures and cash runway into the second half of 2028.
• The combined company will operate as Scipher Medicine Corporation on the Nasdaq exchange, with pre-merger Scipher Medicine Corporation equity holders owning approximately 68 percent of the combined entity and pre-merger Chemomab Therapeutics equity holders owning approximately 32 percent on a fully diluted basis.
• Chemomab Therapeutics shareholders will receive contingent value rights tied to specified nebokitug clinical and commercial milestones, protecting legacy shareholders against value creation that occurs after their equity contribution has been diluted.
• The reverse merger structure delivers Scipher Medicine Corporation a public listing without the friction and valuation risk of a conventional biotech initial public offering, and simultaneously provides Chemomab Therapeutics shareholders with exposure to a revenue-generating precision immunology business.
• Nebokitug is being repositioned from its fibrosis-focused development history into a rheumatoid arthritis Phase 2 trial that will use standard 12-week FDA endpoints combined with AI-guided patient enrollment through Scipher Medicine Corporation’s PrismRA molecular signature test.
• The AI-guided precision trial design has the potential to materially improve the probability of demonstrating clinically meaningful nebokitug efficacy in a molecular signature-defined rheumatoid arthritis population, applying the precision oncology playbook to autoimmune disease.
• Top-line Phase 2 rheumatoid arthritis data are expected in the first half of 2028, positioning that readout as the single most important binary catalyst on the combined company calendar and the value inflection point that management is capitalised to reach.
• The transaction closes in the fourth quarter of 2026 subject to customary regulatory approvals and shareholder votes, and completion is not contingent on financing given the pre-committed 30 million dollar private placement.
• The Northpond Ventures, Khosla Ventures, Blue Owl Healthcare Opportunities, and Neuberger Berman syndicate provides high-quality institutional endorsement and creates natural liquidity providers on the post-merger register, reducing the small-cap technical selling risks that often affect newly public biotech companies.
• The combined company will be one of very few precision immunology developers owning both a differentiated clinical asset and the AI-guided patient selection platform, and successful execution of the nebokitug Phase 2 trial would validate both the therapeutic thesis and the AI Network Medicine platform methodology simultaneously.